Where the stock stands
Aurobindo Pharma, a Healthcare-sector company, last traded at ₹1706.9 in the session on October 12, up 0.82% from the previous close of ₹1693.0. That gain came on a day when the Nifty was down 0.7%, so the stock moved against the broader index in this snapshot. The data does not say why.
On valuation, the pack shows a price-to-earnings ratio of 26.67, meaning the share price is about 26.67 times annual earnings per share of ₹64, and a price-to-book ratio of 2.62. The dividend yield is 0.23%. Over the past year the stock has gained roughly 58.1%, which places it near the upper end of its range rather than in the middle of it.
What the smart-money flow shows
There is nothing to report here, and that absence is itself the finding. The evidence pack carries no futures and options positioning, no named bulk or block deals, no institutional buying or selling streaks and no insider filings for Aurobindo Pharma. None of the usual footprints of large money are on record in this data, so no conclusion about institutional interest, accumulation or distribution can be drawn from it.
The technical picture
One point on timing first: the technical readings are computed off the close of October 9, which was ₹1693.0, not the latest traded price of ₹1706.9. Measured from that close, the stock sat 2.7% below its 52-week high of ₹1740 and 56.74% above its 52-week low of ₹1080.1. It was trading above both its 50-day and 200-day simple moving averages (the average closing price over those windows), and the pack flags neither a golden cross nor a death cross, the crossovers of those two averages that chartists watch.
Momentum readings were middling. The 14-day relative strength index, a gauge of how stretched recent buying or selling has been, sat at 53.3, in neutral territory. Relative volume was 0.97, meaning turnover was close to its usual level rather than unusually heavy or light. Returns were modest over short windows, about 0.96% over one week and 1.47% over one month, and larger over longer ones, about 9.02% over three months and 58.1% over a year. The picture is of a stock that rose sharply over the year and has moved sideways-to-higher in recent weeks.
Catalysts and what to watch
The catalyst feed lists a regulatory approval six times, on each date from October 7 to October 12, all under the same headline: Aurobindo Pharma shares in focus after USFDA approval for Perampanel. This is one reported event repeated by the feed, not six separate approvals, and it is a report rather than a confirmed filing in this data. Separately, a headline from Alice Blue said a subsidiary unit, Unit-IV, had received VAI status from the US FDA, and a headline from Univest described the stock as up 2.19% on one day about three days before this snapshot. Another Univest headline described the share price as near its peak, which agrees with the stock sitting 2.7% under its 52-week high.
What is observable from here: whether the company itself confirms the reported approval through an exchange filing, whether any bulk, block or insider records appear where there are none today, how relative volume behaves if the price approaches the ₹1740 high, and whether the stock stays above its 50-day and 200-day averages. The data establishes the price position, the valuation multiples and a reported regulatory headline; it does not establish what drove the past year's gain or show any record of institutional positioning.